SCHEMBL848499

SCHEMBL848499

CNc1ccccc1C(C)=O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.64
KDM4E B2RXH2 3/20 0.64
ATM Q13315 1/20 0.64
AKR1C3 P42330 2/20 0.50
AKR1C2 P52895 2/20 0.50
PDK1 Q15118 1/20 0.50
PDK2 Q15119 1/20 0.50
PDK3 Q15120 1/20 0.50
PDK4 Q16654 1/20 0.50
CNR2 P34972 1/20 0.47
CYP2C19 P33261 1/20 0.46
ALDH1A1 P00352 3/20 0.45
RECQL P46063 2/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
L3MBTL1 Q9Y468 2/20 0.43
AKR1B10 O60218 1/20 0.43
AKR1B1 P15121 1/20 0.43
AKR1C4 P17516 1/20 0.43
AKR1C1 Q04828 1/20 0.43
LMNA P02545 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31087257 1.00 POLB (0.64) POLBKDM4EATMAKR1C3AKR1C2
Hydrochloric Acid SCHEMBL15974089 0.98 POLB (0.62) POLBKDM4EATMAKR1C3AKR1C2
SCHEMBL13252224 0.88 POLB (0.56) POLBKDM4EATMAKR1C3AKR1C2
SCHEMBL25449209 0.84 AKR1C3 (0.66) POLBKDM4EAKR1C3AKR1C2PDK1
SCHEMBL8628627 0.84 POLB (0.67) POLBKDM4EATMAKR1C3CYP2C19
SCHEMBL28818947 0.83 AKR1C3 (0.47) POLBKDM4EATMAKR1C3AKR1C2
SCHEMBL27723917 0.83 POLB (0.60) POLBKDM4EATMCYP2C19ALDH1A1
N-Methylanthranilic Acid SCHEMBL130356 0.82 KDM4E (0.64) POLBKDM4EATMAKR1C3AKR1C2
SCHEMBL6964053 0.82 KDM4E (0.64) POLBKDM4EATMCYP2C19ALDH1A1
N-Methylanthranilic Acid SCHEMBL29381752 0.82 KDM4E (0.64) POLBKDM4EATMAKR1C3AKR1C2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110669058-A Tricyclic quinolone carboxylic acid and preparation method thereof 江西农业大学 2020-01-10 CN claimed
EP-3229612-B1 USE OF FLAVOR COMPOSITIONS AND PET FOOD PRODUCTS CONTAINING THE SAME MARS INC (US) 2024-06-26 EP disclosed
WO-2024091450-A1 COMPOUNDS AND METHODS FOR TREATING CANCER THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-05-02 WO disclosed
US-20230255933-A1 ANTIVIRAL USE OF FABP4 MODULATING COMPOUNDS CRESCENTA BIOSCIENCES (US) 2023-08-17 US disclosed
US-20230137773-A1 RAS INHIBITORY PEPTIDES AND USES THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2023-05-04 US disclosed
US-20230137773-A1 RAS INHIBITORY PEPTIDES AND USES THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2023-05-04 US disclosed
US-11377476-B2 Ras inhibitory peptides and uses thereof PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2022-07-05 US disclosed
WO-2022118186-A1 SENOTHERAPEUTIC COMPOUND BIONEXA S.R.L. (IT) 2022-06-09 WO disclosed
EP-3943108-A1 ANTIGEN-BINDING MOLECULE CONTAINING ANTIGEN-BINDING DOMAIN OF WHICH BINDING ACTIVITY TO ANTIGEN IS CHANGED DEPENDING ON MTA, AND LIBRARY FOR OBTAINING SAID ANTIGEN-BINDING DOMAIN CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2022-01-26 EP disclosed
EP-3206689-B1 INHIBITORS OF LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE AND USES THEREOF LA JOLLA INST OF ALLERGY & IMMUNOLOGY (US) 2021-12-08 EP disclosed
US-4997840-A Quinolone sulphonates having antihypertensive activity THE BOOTS COMPANY, PLC (GB) 1991-03-05 US disclosed
EP-0330340-A1 Therapeutic agents The Boots Company PLC (GB) 1989-08-30 EP disclosed
WO-1989007593-A1 THERAPEUTIC AGENTS THE BOOTS COMPANY PLC (GB) 1989-08-24 WO disclosed
US-4414416-A Certain diacetyl-amino-phenolic derivatives FISONS LIMITED (GB) 1983-11-08 US disclosed
US-4328341-A Process for preparing certain pyrano[3,2-g]quinoline 2,8-dicarboxylates and 4-oxo-quinoline-2-carboxylates FISONS LIMITED (GB) 1982-05-04 US disclosed
EP-0030423-A1 A process for the production of 1,4-dihydro-4-oxo-quinoline-2-carboxylic acids, or salts, esters or amides thereof and intermediates therefor FISONS plc (GB) 1981-06-17 EP disclosed
US-4198496-A COBALT COMPONENT, MAGNESIUM OR MANGANESE CHLORIDE, IODIDE OR CARBOXYLIC ACID SATL, ORGANOALUMINUM HALIDE AS CATALYST THE FIRESTONE TIRE & RUBBER COMPANY (US) 1980-04-15 US disclosed
US-4051308-A Process for polymerizing butadiene with cobalt complex, AlR3 and CS2 THE FIRESTONE TIRE & RUBBER COMPANY (US) 1977-09-27 US disclosed
US-3993856-A CATALYST OF COBALT COMPOUND, HYDRO- OR HYDROCARBYLALUMINUM DIHALIDE, AND CARBON DISULFIDE THE FIRESTONE TIRE & RUBBER COMPANY (US) 1976-11-23 US disclosed
US-3956390-A Preparation of amines SCHERING CORPORATION (US) 1976-05-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230137773-A1 RAS INHIBITORY PEPTIDES AND USES THEREOF TPX2, RASGRP1, KRAS POLB 4522/4885KDM4E 4235/4885ATM 4654/4885
US-20230255933-A1 ANTIVIRAL USE OF FABP4 MODULATING COMPOUNDS FABP1, FABP4, FABP5 POLB 3010/4885KDM4E 1451/4885ATM 4851/4885
US-11377476-B2 Ras inhibitory peptides and uses thereof KRAS, RASGRP1, RASGRP3 POLB 3990/4885KDM4E 3376/4885ATM 4701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.